What the Study Found (In Plain English)
Published in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021), this phase iii randomized trial evaluating 203 human participants investigated: Dengue is the most significant mosquito-borne viral disease; there are no specific therapeutics. Key clinical takeaway: A 3-day 1 daily dose of 400 µg/kg oral ivermectin was safe and accelerated NS1 antigenemia clearance in dengue patients. However, clinical efficacy of ivermectin was not observed at this dosage regimen.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021-05-18; N = 203; Rigor 88/100): A 3-day 1 daily dose of 400 µg/kg oral ivermectin was safe and accelerated NS1 antigenemia clearance in dengue patients. However, clinical efficacy of ivermectin was not observed at this dosage regimen.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.